retatrutide type 2 diabetes phase 2 results 2024 More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Triple hormone receptor agonist retatrutide

Activation of astrocytes in the dorsomedial striatum facilitates transition from habitual to goal-directed reward-seeking behavior

Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, MASLD, and other cardio-kidney-metabolic conditions (Diabetes, Obesity & Metabolism)

Total weight loss continues to accumulate through 1218 months of treatment in most patients

Ethics declarations Ethical Approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards

Exenatide and the Treatment of Patients With Parkinsons Disease